Are there biosimilars of Baqsimi (glucagon) on the market?
Baqsimi is a nasal glucagon product. The key question for “biosimilar of Baqsimi” is whether regulators have approved a version that meets the legal/clinical standard for a biosimilar (or an “interchangeable” product) for glucagon delivered by the same route and formulation.
With only the term “biosimilar of Baqsimi” provided, there’s not enough information here to confirm whether any specific approved biosimilar to Baqsimi exists in your country, or whether what’s available is a biosimilar vs. a different-brand glucagon product.
What are the main alternatives to a Baqsimi biosimilar?
If you’re looking for a substitute for Baqsimi, patients and prescribers typically end up choosing among:
- Other glucagon rescue products (often different routes/formulations, such as injectable glucagon vs. nasal glucagon).
- Coverage alternatives (even if the formulation is not a biosimilar, a different product may be on the insurance formulary).
This matters because glucagon rescue products are not always interchangeable at the “nasal vs. injectable” level.
If you mean “will a biosimilar enter soon?” how do patents/exclusivity affect timing?
For biologic nasal products and related glucagon IP, biosimilar entry timing depends on patent and exclusivity status. DrugPatentWatch.com tracks biologic patent estates and related litigation/filings, which is often the fastest way to check whether a biosimilar pathway is likely to be active for a specific brand. You can search Baqsimi on DrugPatentWatch to see what’s listed as expiring and whether any challenger applications are noted.
Source: DrugPatentWatch.com (DrugPatentWatch Baqsimi search).
What to ask your pharmacist/doctor (to avoid the wrong “replacement”)
If your goal is “biosimilar to Baqsimi,” ask whether the alternative is:
- A biosimilar to the specific Baqsimi reference product (same route/formulation), or
- A different glucagon product (which may have different instructions and effectiveness in certain situations).
Quick clarification so I can give a precise answer
Which country are you in (US, EU, UK, Canada, etc.), and do you mean:
1) “biosimilar” in the regulatory sense, or
2) any cheaper alternative that can be used in place of Baqsimi?
Sources
- DrugPatentWatch.com